Angiomyolipoma medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}}{{Faizan}} | {{CMG}} {{AE}}{{Faizan}} | ||
==Overview== | |||
==Treatment== | ==Treatment== | ||
| Line 17: | Line 19: | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 19:10, 21 September 2015
|
Angiomyolipoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiomyolipoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Angiomyolipoma medical therapy |
|
Risk calculators and risk factors for Angiomyolipoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
Treatment
Angiomyolipomas found incidentally usually require no therapy (when small), although follow-up is recommended to assess for growth. Small solitary AMLs (< 20 mm) probably do not require follow-up due to their slow growth.
Larger AMLs, or those that have been symptomatic, can be electively embolised and/or resected with a partial nephrectomy.
Lesions that present with retroperitoneal haemorrhage often requires emergency embolisation as a life saving measure.